USFDA completes PAI of Cipla's Qidong unit

Cipla Limited has announced that a pre-approval inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of Cipla (Jiangsu) Pharmaceutical Co., Ltd. (subsidiary of the Company) located in Qidong, Jiangsu Province, China from 26th February, 2024 to 1st March, 2024.

The inspection concluded with zero Form 483 observations.

Shares of Cipla Limited was last trading in BSE at Rs. 1470.60 as compared to the previous close of Rs. 1480.60. The total number of shares traded during the day was 23905 in over 2507 trades.

The stock hit an intraday high of Rs. 1486.05 and intraday low of 1460.25. The net turnover during the day was Rs. 35211750.00.

Source : Equity Bulls

Keywords

Cipla INE059A01026 PAI USFDA QidongUnit China